CN111304149B - 一种支持hek293细胞悬浮培养的无血清无蛋白培养基及其制备方法和应用 - Google Patents
一种支持hek293细胞悬浮培养的无血清无蛋白培养基及其制备方法和应用 Download PDFInfo
- Publication number
- CN111304149B CN111304149B CN202010108434.9A CN202010108434A CN111304149B CN 111304149 B CN111304149 B CN 111304149B CN 202010108434 A CN202010108434 A CN 202010108434A CN 111304149 B CN111304149 B CN 111304149B
- Authority
- CN
- China
- Prior art keywords
- free
- serum
- protein
- vitamin
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001963 growth medium Substances 0.000 title claims abstract description 37
- 238000004114 suspension culture Methods 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 239000002609 medium Substances 0.000 claims description 38
- 229940088594 vitamin Drugs 0.000 claims description 25
- 229930003231 vitamin Natural products 0.000 claims description 25
- 235000013343 vitamin Nutrition 0.000 claims description 25
- 239000011782 vitamin Substances 0.000 claims description 25
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 23
- 229940024606 amino acid Drugs 0.000 claims description 23
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 23
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 claims description 22
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 22
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 21
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 20
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 20
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 20
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 20
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 18
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 16
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 16
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 16
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 16
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 15
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 15
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 15
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 15
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 14
- 239000011573 trace mineral Substances 0.000 claims description 14
- 235000013619 trace mineral Nutrition 0.000 claims description 14
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 claims description 13
- 239000004313 iron ammonium citrate Substances 0.000 claims description 13
- 235000000011 iron ammonium citrate Nutrition 0.000 claims description 13
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 229930091371 Fructose Natural products 0.000 claims description 11
- 239000005715 Fructose Substances 0.000 claims description 11
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 11
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 11
- 229960003080 taurine Drugs 0.000 claims description 11
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 10
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000005700 Putrescine Substances 0.000 claims description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 10
- 230000000996 additive effect Effects 0.000 claims description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 10
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 claims description 10
- 229960003237 betaine Drugs 0.000 claims description 10
- 229920003045 dextran sodium sulfate Polymers 0.000 claims description 10
- 229960004642 ferric ammonium citrate Drugs 0.000 claims description 10
- 239000000413 hydrolysate Substances 0.000 claims description 10
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 claims description 10
- 229940113082 thymine Drugs 0.000 claims description 10
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 9
- 235000019743 Choline chloride Nutrition 0.000 claims description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 229930003756 Vitamin B7 Natural products 0.000 claims description 9
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 9
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 9
- 235000021342 arachidonic acid Nutrition 0.000 claims description 9
- 229940114079 arachidonic acid Drugs 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 229940107161 cholesterol Drugs 0.000 claims description 9
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 9
- 229960003178 choline chloride Drugs 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- 229960002413 ferric citrate Drugs 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 9
- 229960004488 linolenic acid Drugs 0.000 claims description 9
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 9
- 230000003204 osmotic effect Effects 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- 229940054269 sodium pyruvate Drugs 0.000 claims description 9
- 235000019156 vitamin B Nutrition 0.000 claims description 9
- 239000011720 vitamin B Substances 0.000 claims description 9
- 235000011912 vitamin B7 Nutrition 0.000 claims description 9
- 239000011735 vitamin B7 Substances 0.000 claims description 9
- IOCJWNPYGRVHLN-MMALYQPHSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O IOCJWNPYGRVHLN-MMALYQPHSA-N 0.000 claims description 8
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims description 8
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- 229960005261 aspartic acid Drugs 0.000 claims description 8
- UNTBPXHCXVWYOI-UHFFFAOYSA-O azanium;oxido(dioxo)vanadium Chemical compound [NH4+].[O-][V](=O)=O UNTBPXHCXVWYOI-UHFFFAOYSA-O 0.000 claims description 8
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 8
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 claims description 8
- 235000012343 cottonseed oil Nutrition 0.000 claims description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 8
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 8
- WFTCFVUQORELJZ-USHJOAKVSA-L disodium;(2s)-2-amino-3-(4-oxidophenyl)propanoate;dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)[C@@H](N)CC1=CC=C([O-])C=C1 WFTCFVUQORELJZ-USHJOAKVSA-L 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 229960002989 glutamic acid Drugs 0.000 claims description 8
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 8
- 235000020778 linoleic acid Nutrition 0.000 claims description 8
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 8
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 8
- 235000019136 lipoic acid Nutrition 0.000 claims description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 8
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 8
- CNFDGXZLMLFIJV-UHFFFAOYSA-L manganese(II) chloride tetrahydrate Chemical compound O.O.O.O.[Cl-].[Cl-].[Mn+2] CNFDGXZLMLFIJV-UHFFFAOYSA-L 0.000 claims description 8
- 229960003966 nicotinamide Drugs 0.000 claims description 8
- 235000005152 nicotinamide Nutrition 0.000 claims description 8
- 239000011570 nicotinamide Substances 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 8
- 235000011164 potassium chloride Nutrition 0.000 claims description 8
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 claims description 8
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 8
- 235000015921 sodium selenite Nutrition 0.000 claims description 8
- 239000011781 sodium selenite Substances 0.000 claims description 8
- 229960001471 sodium selenite Drugs 0.000 claims description 8
- 229960002663 thioctic acid Drugs 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 235000005074 zinc chloride Nutrition 0.000 claims description 8
- 239000011592 zinc chloride Substances 0.000 claims description 8
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 7
- 229930182816 L-glutamine Natural products 0.000 claims description 7
- 229930182844 L-isoleucine Natural products 0.000 claims description 7
- 239000004395 L-leucine Substances 0.000 claims description 7
- 235000019454 L-leucine Nutrition 0.000 claims description 7
- 229930195722 L-methionine Natural products 0.000 claims description 7
- 229930182821 L-proline Natural products 0.000 claims description 7
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- 229930003270 Vitamin B Natural products 0.000 claims description 7
- 229960003767 alanine Drugs 0.000 claims description 7
- 229960001230 asparagine Drugs 0.000 claims description 7
- 229940092124 calcium citrate malate Drugs 0.000 claims description 7
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- 229960003136 leucine Drugs 0.000 claims description 7
- 229960004452 methionine Drugs 0.000 claims description 7
- 229960002429 proline Drugs 0.000 claims description 7
- 229960001153 serine Drugs 0.000 claims description 7
- 229960002898 threonine Drugs 0.000 claims description 7
- 229960004295 valine Drugs 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 9
- 230000012010 growth Effects 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 6
- 230000010261 cell growth Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 238000001890 transfection Methods 0.000 abstract description 4
- 238000010008 shearing Methods 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 75
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 22
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 15
- 229960002477 riboflavin Drugs 0.000 description 15
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 150000003722 vitamin derivatives Chemical class 0.000 description 13
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 9
- 229930003471 Vitamin B2 Natural products 0.000 description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 8
- 235000019164 vitamin B2 Nutrition 0.000 description 8
- 239000011716 vitamin B2 Substances 0.000 description 8
- 235000019158 vitamin B6 Nutrition 0.000 description 8
- 239000011726 vitamin B6 Substances 0.000 description 8
- 229940011671 vitamin b6 Drugs 0.000 description 8
- 229930003451 Vitamin B1 Natural products 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 7
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 7
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 7
- 235000019192 riboflavin Nutrition 0.000 description 7
- 239000002151 riboflavin Substances 0.000 description 7
- 229960003495 thiamine Drugs 0.000 description 7
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 7
- 239000011747 thiamine hydrochloride Substances 0.000 description 7
- 229960000344 thiamine hydrochloride Drugs 0.000 description 7
- 235000010374 vitamin B1 Nutrition 0.000 description 7
- 239000011691 vitamin B1 Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960005190 phenylalanine Drugs 0.000 description 5
- 235000019766 L-Lysine Nutrition 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 239000012822 autophagy inhibitor Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000019522 cellular metabolic process Effects 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000012154 double-distilled water Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 101150084750 1 gene Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- OYPRJOBELJOOCE-BKFZFHPZSA-N Calcium-45 Chemical compound [45Ca] OYPRJOBELJOOCE-BKFZFHPZSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 239000004469 amino acid formulation Substances 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- 229940016114 calcium malate Drugs 0.000 description 1
- 235000011038 calcium malates Nutrition 0.000 description 1
- QXDHJHQRJCJRAU-UHFFFAOYSA-N calcium;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Ca].OC(=O)CC(O)(C(O)=O)CC(O)=O QXDHJHQRJCJRAU-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940100125 glycine 25 mg Drugs 0.000 description 1
- 229940026527 glycine 50 mg Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- -1 iron ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/74—Undefined extracts from fungi, e.g. yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种支持HEK293细胞悬浮培养的无血清无蛋白培养基及其制备方法和应用,属于细胞工程技术领域。本发明的无血清无蛋白培养基根据细胞体外生长的营养需求选择不同营养物质以替代动物血清所发挥的作用,并对不同营养物质的比例进行了合理调整,通过进一步添加抗剪切力物质和抗结团物质,实现了不需要补充血清也可以维持高密度悬浮培养HEK293细胞,并维持细胞的正常形态,使细胞分散不结团,同时保持正常的生长速度,利于目的基因的转染和表达。
Description
技术领域
本发明涉及一种持HEK293细胞悬浮培养的无血清无蛋白培养基,以及该培养基的制备方法和应用,属于细胞工程技术领域。
背景技术
HEK293细胞是被广泛用于生产蛋白、疫苗、抗癌试剂及重组腺病毒包被的人源哺乳动物细胞系。细胞株最早于1976年由加拿大McMaster大学F.L.Graham与J.S.Miley用DNA转染技术构建而成。HEK293细胞是经5型腺病毒75株系转化、含有Ads E1区的人胚肾亚三倍体细胞系。HEK293细胞作为E1区缺陷互补细胞系,可持续表达ElA和E1B基因。HEK293细胞在培养体系中能够快速增长,经过适当的驯化可实现高密度悬浮培养,以用于大规模表达。
细胞培养基是决定细胞体外生长代谢最重要、最直接的环境因素。目前大多数合成细胞培养基均需要补充动物血清才能支持细胞的体外生长和增殖,而使用动物血清可能使培养物遭受动物性病原微生物污染和引入外源蛋白,给重组蛋白细胞产品的分离纯化带来很大困难。并且,HEK293细胞在悬浮培养过程中极易结团,细胞团直接影响细胞活性,导致HEK293细胞无法高密度扩增、连续传代。
现有技术中,进口品牌的HEK293悬浮培养无血清培养基配方保密且价格昂贵,还存在培养效果不佳、蛋白表达量低下和细胞结团等问题。公布号为CN109294976A的中国发明专利公开了一种支持HEK293细胞悬浮培养的无血清培养基,该培养基能维持HEK293细胞高密度悬浮培养,并维持正常的细胞形态,使细胞分散不结团,但是培养基中含有大量蛋白成分,如白蛋白、胰岛素以及转铁蛋白等,一方面增加了使用成本,另一方面不利于下游蛋白的纯化和生产。
发明内容
本发明的目的是提供一种支持HEK293细胞悬浮培养的无血清无蛋白培养基,该培养基中未添加蛋白成分,有利于下游蛋白的分离纯化,并减少血清的外源病毒污染等潜在风险。
本发明还提供一种支持HEK293细胞悬浮培养的无血清无蛋白培养基的制备方法。
本发明还提供一种支持HEK293细胞悬浮培养的无血清无蛋白培养基的应用。
为了实现以上目的,本发明所采用的技术方案是:
一种支持HEK293细胞悬浮培养的无血清无蛋白培养基,包括氨基酸、微量元素、维生素、脂类物质、无机盐、抗结团物质和添加剂;所述抗结团物质的组成为:葡聚糖硫酸钠25~150mg/L,柠檬酸铁铵5~15mg/L;所述添加剂的组成为:腐胺0.1~1mg/L,胸腺嘧啶0.6~2.4mg/L,抗坏血酸磷酸酯镁1~5mg/L,乙醇胺1.5~12.5mg/L,金精三羧酸1~10mg/L,次黄嘌呤1~10mg/L,甲基-β-环糊精25~100mg/L,甜菜碱500~1000mg/L,牛磺酸60~180mg/L,海藻糖75~150mg/L,果糖500~1500mg/L,D-葡萄糖4000~8000mg/L,酵母水解物1000~3000mg/L,棉籽水解物1000~3000mg/L,Kolliphor p188 3000~6000mg/L。
本发明的无血清无蛋白培养基根据HEK293细胞生长需要的营养需求,由氨基酸、微量元素、维生素、脂类物质、无机盐、抗结团物质和添加剂等组成,培养基中不含动物源组分、不含蛋白,成分明确,不需要添加血清即可维持HEK293细胞的高密度悬浮培养。
HEK293细胞在悬浮培养过程中极易结团,细胞团直接影响细胞活性,导致HEK293细胞无法高密度扩增、连续传代。为了使HEK293细胞在培养体系中迅速增长,经过适当的驯化后实现高密度悬浮培养,以用于大规模表达,本发明在培养基中加入了抗结团物质葡聚糖硫酸钠和柠檬酸铁铵,葡聚糖硫酸钠和柠檬酸铁铵能促使单个细胞的悬浮,减少细胞在高密度细胞培养的细胞结团现象。除了作为抗结团物质外,柠檬酸铁铵还能有效地把铁离子传递给细胞,从而代替转铁蛋白。
上述添加剂中,腐胺具有促进蛋白质和核酸合成及调节细胞内pH的作用。胸腺嘧啶和次黄嘌呤是DNA补救合成途径中的主要前体物。抗坏血酸磷酸酯镁与维生素C作用相似,但比维生素C更加稳定。乙醇胺是构成细胞膜磷脂的重要成分。金精三羧酸可以刺激胰岛素样生长因子的活化,从而代替胰岛素,促进细胞利用葡萄糖和氨基酸。甲基-β-环糊精促进细胞更好的利用脂类物质。牛磺酸是一种含硫的非蛋白氨基酸,虽然不参与蛋白质合成,但它却与胱氨酸、半胱氨酸的代谢密切相关。甜菜碱和牛磺酸作为内质网蛋白表达化学伴侣能引起内质网扩张,从而提高蛋白(或转基因)的表达量。海藻糖、果糖、D-葡萄糖等作为碳水化合物主要为细胞生长提供碳源,为氨基酸、DNA合成提供前体物质。果糖除了可以提供碳源外,还有利于维持培养基pH的稳定性。由于HEK293细胞在重组蛋白表达中往往表达水平偏低,添加酵母水解物和棉籽水解物可以提高重组蛋白的表达水平。Kolliphorp188(市售商品)可以降低细胞悬浮培养过程中产生的剪切力对细胞的损伤。
优选的,所述抗结团物质的组成为:葡聚糖硫酸钠50~120mg/L,柠檬酸铁铵8~12mg/L。更优选的,抗结团物质中葡聚糖硫酸钠100mg/L,柠檬酸铁铵10mg/L。
优选的,所述添加剂的组成为:腐胺0.3~0.4mg/L,胸腺嘧啶1.0~1.5mg/L,抗坏血酸磷酸酯镁2~3mg/L,乙醇胺4~6mg/L,金精三羧酸2~3mg/L,次黄嘌呤6.0~7.5mg/L,甲基-β-环糊精45~55mg/L,甜菜碱650~750mg/L,牛磺酸100~150mg/L,海藻糖90~110mg/L,果糖950~1050mg/L,D-葡萄糖5500~6500mg/L,酵母水解物1800~2200mg/L,棉籽水解物1800~2200mg/L,Kolliphor p188 4500~5500mg/L。
在上述无血清无蛋白培养基中,氨基酸可以为本领域常用的氨基酸配方。具体的,所述氨基酸的组成为:L-组氨酸盐酸盐一水合物50~150mg/L,L-异亮氨酸100~200mg/L,L-亮氨酸150~200mg/L,L-赖氨酸250~300mg/L,L-蛋氨酸25~100mg/L,L-苯丙氨酸50~150mg/L,L-苏氨酸100~200mg/L,L-色氨酸25~75mg/L,L-缬氨酸100~200mg/L,甘氨酸25~75mg/L,L-丙氨酸6~25mg/L,L-谷氨酰胺1000~2000mg/L,L-精氨酸盐酸盐200~600mg/L,L-天(门)冬酰胺150~300mg/L,L-天冬氨酸20~60mg/L,L-半胱氨酸盐酸盐一水合物25~75mg/L,L-胱氨酸盐酸盐40~100mg/L,L-谷氨酸10~30mg/L,L-脯氨酸55~165mg/L,L-丝氨酸50~150mg/L,L-酪氨酸二钠盐二水合物100~200mg/L。
氨基酸是组成蛋白质的主要成分,也是细胞生长所必须的能源的提供者。本发明的无血清无蛋白培养基中氨基酸主要有21种,其中9种为必须氨基酸,12种为非必须氨基酸。由于传统培养基的氨基酸浓度较低,只能维持细胞的短期贴壁生长,为了支持高密度的细胞悬浮培养,本发明大幅度提高了培养基中的氨基酸浓度,同时注重氨基酸之间的平衡。
优选的,所述氨基酸的组成为:L-组氨酸盐酸盐一水合物90~100mg/L,L-异亮氨酸160~170mg/L,L-亮氨酸170~185mg/L,L-赖氨酸265~280mg/L,L-蛋氨酸45~55mg/L,L-苯丙氨酸100~110mg/L,L-苏氨酸155~165mg/L,L-色氨酸45~55mg/L,L-缬氨酸150~165mg/L,甘氨酸50~60mg/L,L-丙氨酸10~18mg/L,L-谷氨酰胺1600~1650mg/L,L-精氨酸盐酸盐435~450mg/L,L-天(门)冬酰胺190~210mg/L,L-天冬氨酸35~45mg/L,L-半胱氨酸盐酸盐一水合物45~60mg/L,L-胱氨酸盐酸盐55~70mg/L,L-谷氨酸18~25mg/L,L-脯氨酸110~120mg/L,L-丝氨酸65~80mg/L,L-酪氨酸二钠盐二水合物160~175mg/L。
在上述无血清无蛋白培养基中,微量元素可以为本领域常用的微量元素配方。具体的,所述微量元素的组成为:偏钒酸铵0.0001~0.1mg/L,亚硒酸钠0.01~0.25mg/L,四水氯化亚锰0.1~0.5mg/L,五水硫酸铜0.1~0.6mg/L,氯化锌0.2~1.0mg/L。
微量元素是细胞生长和代谢中许多重要酶的辅基和辅酶,本发明在HEK293细胞悬浮培养基中添加钒、硒、锰、铜、锌作为微量元素,能够作为催化剂参与细胞代谢,协助输送宏量元素并影响核酸代谢。优选的,所述微量元素的组成为:偏钒酸铵0.0008~0.0012mg/L,亚硒酸钠0.05~0.07mg/L,四水氯化亚锰0.1~0.3mg/L,五水硫酸铜0.3~0.5mg/L,氯化锌0.5~0.75mg/L。
在上述无血清无蛋白培养基中,维生素可以为本领域常用的维生素配方。具体的,所述维生素的组成为:维生素H(生物素)0.01~1mg/L,叶酸5~20mg/L,维生素B2(核黄素)0.1~1mg/L,硫辛酸0.1~1mg/L,维生素B12 0.5~4mg/L,i-肌醇20~60mg/L,维生素B6(盐酸吡哆醇)2~10mg/L,维生素B1(盐酸硫胺)2~10mg/L,维生素C 2.5~10mg/L,维生素E1~10mg/L,D-泛酸钙1~10mg/L,烟酰胺1~10mg/L,氯化胆碱20~60mg/L。
维生素是细胞生长和代谢中许多酶的辅基和辅酶,细胞培养基中的维生素主要是B族维生素,本发明在HEK293细胞悬浮培养基中添加包括B族维生素在内的多种复合维生素,可以明显促进HEK293细胞的悬浮增殖。
上述维生素中,维生素H作为多种酶的辅酶,参与体内的脂肪酸和碳水化合物的代谢,还可促进蛋白质的合成。叶酸是一碳单位转移酶系的辅酶,还参与嘌呤和胸腺嘧啶的合成。维生素B2是一些重要的氧化还原酶的辅基,如琥珀酸脱氢酶、黄嘌呤氧化酶及NADH脱氢酶等,主要参与呼吸链能量产生等生化反应。维生素B6主要以磷酸吡多醛(PLP)的形式参与近百种酶的反应,多数与氨基酸代谢有关,包括转氨基、脱羧、侧链裂解、脱水及转硫化作用等。维生素E是细胞膜的重要组成成分和主要抗氧化剂。烟酰胺是辅酶I和辅酶II的组成部分,为许多脱氢酶的辅酶。氯化胆碱既是细胞膜的成分,又能促进脂肪分解。
优选的,所述维生素的组成为:维生素H(生物素)0.05~0.15mg/L,叶酸8~12mg/L,维生素B2(核黄素)0.3~0.5mg/L,硫辛酸0.3~0.5mg/L,维生素B12 1.5~2.5mg/L,i-肌醇30~40mg/L,维生素B6(盐酸吡哆醇)5~7mg/L,维生素B1(盐酸硫胺)5.5~7.5mg/L,维生素C 4~6mg/L,维生素E 2~3mg/L,D-泛酸钙4~5mg/L,烟酰胺4~6mg/L,氯化胆碱25~35mg/L。
在上述无血清无蛋白培养基中,脂类物质可以为本领域常用的脂类物质配方。具体的,所述脂类物质的组成为:亚麻酸0.008~0.8mg/L,地塞米松0.008~0.8mg/L,亚油酸0.05~0.5mg/L,胆固醇1~10mg/L,花生四烯酸0.0002~0.02mg/L。
脂类物质的添加可以减少细胞对其生物合成的需要,本发明在HEK293细胞悬浮培养基中添加亚麻酸、地塞米松、亚油酸、胆固醇和花生四烯酸作为脂类物质,可以为细胞提供脂类营养,促进细胞的新陈代谢、分裂速率,促进转基因产物的表达。
优选的,所述脂类物质的组成为:亚麻酸0.05~0.15mg/L,地塞米松0.05~0.15mg/L,亚油酸0.2~0.12mg/L,胆固醇2~3mg/L,花生四烯酸0.001~0.005mg/L。
在上述无血清无蛋白培养基中,无机盐可以为本领域常用的无机盐配方。具体的,所述无机盐的组成为:柠檬酸铁50~150mg/L,柠檬酸钠100~200mg/L,磷酸氢二钠150~300mg/L,氯化钾300~500mg/L,碳酸氢钠2000~3000mg/L,丙酮酸钠750~1500mg/L,硫酸镁50~150mg/L,硝酸钙100~300mg/L,柠檬酸苹果酸钙25~100mg/L。
本发明在HEK293细胞悬浮培养基中添加上述无机盐可以维持细胞膜的渗透压,并协助有机分子的转运。此外,无机盐中K+、Ca2+、Cu2+、Mg2+等参与细胞代谢及信号传导,并促进细胞贴壁和细胞增殖。
在上述无机盐中,柠檬酸铁能有效地把铁离子传递给细胞,从而代替转铁蛋白。柠檬酸钠与丙酮酸钠还可以作为细胞培养中的替代碳源。
优选的,所述无机盐的组成为:柠檬酸铁70~80mg/L,柠檬酸钠140~155mg/L,磷酸氢二钠280~290mg/L,氯化钾305~315mg/L,碳酸氢钠2150~2250mg/L,丙酮酸钠1050~1150mg/L,硫酸镁85~95mg/L,硝酸钙230~240mg/L,柠檬酸苹果酸钙45~55mg/L。
本发明的无血清无蛋白培养基根据细胞体外生长的营养需求选择不同营养物质以替代动物血清所发挥的作用,并对不同营养物质的比例进行了合理调整,通过进一步添加抗剪切力物质和抗结团物质,实现了不需要补充血清也可以维持高密度悬浮培养HEK293细胞,并维持细胞的正常形态,使细胞分散不结团,同时保持正常的生长速度,利于目的基因的转染和表达。
进一步的,所述无血清无蛋白培养基中还可以添加自噬抑制剂3-甲基腺嘌呤。通常在细胞浓度达到峰值后一天加入3-甲基腺嘌呤至终浓度为8~12mM,优选为10mM。3-甲基腺嘌呤的加入能够提高转基因的表达量。在添加自噬抑制剂前,先将500mM 3-甲基腺嘌呤储备液溶解在0.5M HCl中,然后用7.5%(w/v)NaHCO3溶液将培养物的pH值调节至7.0。
进一步的,所述无血清无蛋白培养基的pH值为6.9~7.2,渗透压为285-305mOsm/kg。为了保证渗透压在上述范围,需要向培养基中添加渗透压调节剂,如氯化钠。
进一步的,所述无血清无蛋白培养基的溶剂为水,如双蒸水、去离子水等。
上述无血清无蛋白培养基的制备方法,包括以下步骤:
1)按照配方准确称取培养基中各组分,在水中溶解混合,得到溶液;
2)调节溶液的pH值为6.9~7.2、渗透压为285-305mOsm/kg,过滤除菌,即得。
步骤1)中,优选的,取上述除水外的组分,根据其各自溶解特性分类溶解,然后混合,加入水至各组分的终浓度。
步骤2)中,调节溶液渗透压所用的渗透压调节剂为氯化钠。
步骤2)中,过滤除菌后分装,保存至4℃。
上述无血清无蛋白培养基在培养HEK293细胞中的应用。
本发明的无血清无蛋白培养基经专门设计,可广泛应用于HEK293细胞的无血清无蛋白悬浮培养及抗体、重组蛋白的生产过程。HEK293细胞的无血清无蛋白培养有利于下游蛋白的分离纯化,并可减少血清的外源病毒污染等潜在风险。
附图说明
图1为实施例1中HEK293F细胞高密度下悬浮生长示意图;
图2为试验例1中HEK293F细胞在实施例1的培养基中连续培养5天的生长趋势图;
图3为试验例2中Western blot验证目的基因TGF-β1在不同培养基中的表达情况。
具体实施方式
下述实施例仅对本发明作进一步详细说明,但不构成对本发明的任何限制。
下述实施例中所涉及的仪器、试剂和材料等,若无特别说明,均为现有技术中已有的常规仪器、试剂和材料等,可通过正规商业途径购买获得。其中,酵母水解物购自Sigma-Aldrich公司;棉籽水解物购自北京鸿润宝顺公司;Kolliphor p188购自Sigma-Aldrich公司。
下述实施例中所涉及的试验方法和检测方法等,若无特别说明,均为现有技术中已有的常规试验方法和检测方法等,均可从本领域的工具书或教科书等中查询获得。
实施例1
本实施例中支持HEK293细胞悬浮培养的无血清无蛋白培养基,组成如下(各物质浓度单位为mg/L):
氨基酸组分:
L-组氨酸盐酸盐一水合物 94.44;
L-异亮氨酸 163.41;
L-亮氨酸 177.15;
L-赖氨酸 273.75;
L-蛋氨酸 50;
L-苯丙氨酸 106.44;
L-苏氨酸 160.35;
L-色氨酸 51.1;
L-缬氨酸 158.55;
甘氨酸 56.25;
L-丙氨酸 13.35;
L-谷氨酰胺 1626;
L-精氨酸盐酸盐 442.5;
L-天(门)冬酰胺 200;
L-天冬氨酸 39.95;
L-半胱氨酸盐酸盐一水合物 52.68;
L-胱氨酸盐酸盐 62.58;
L-谷氨酸 22.05;
L-脯氨酸 115;
L-丝氨酸 72;
L-酪氨酸二钠盐二水合物 167.37;
微量元素组分:
偏钒酸铵 0.001;
亚硒酸钠 0.054;
四水氯化亚锰 0.2;
五水硫酸铜 0.38;
氯化锌 0.58;
维生素组分:
维生素H(生物素) 0.1;
叶酸 10;
维生素B2(核黄素) 0.4;
硫辛酸 0.42;
维生素B12 2.04;
i-肌醇 36;
维生素B6(盐酸吡哆醇) 6;
维生素B1(盐酸硫胺) 6.51;
维生素C 5;
维生素E 2.5;
D-泛酸钙 4.5;
烟酰胺 5;
氯化胆碱 30;
脂类物质:
亚麻酸 0.08;
地塞米松 0.08;
亚油酸 0.168;
胆固醇 2.5;
花生四烯酸 0.002;
无机盐组分:
柠檬酸铁 75;
柠檬酸钠 147.05;
磷酸氢二钠 283.92;
氯化钾 310.874;
碳酸氢钠 2200;
丙酮酸钠 1100;
硫酸镁 90.278;
硝酸钙 236.15;
柠檬酸苹果酸钙 50;
添加剂:
腐胺 0.324;
胸腺嘧啶 1.2112;
抗坏血酸磷酸酯镁 2.5;
乙醇胺 5;
金精三羧酸 2.5;
次黄嘌呤 6.8055;
甲基-β-环糊精 50;
甜菜碱 700;
牛磺酸 125;
海藻糖 100;
果糖 1000;
D-葡萄糖 6000;
酵母水解物 2000;
棉籽水解物 2000;
Kolliphor p188 5000;
抗结团物质:
葡聚糖硫酸钠 100;
柠檬酸铁铵 10;
余量为双蒸水。
本实施例中支持HEK293细胞悬浮培养的无血清无蛋白培养基的制备方法,包括以下步骤:
1)按照配方准确称取培养基中各组分,取除水外的组分,根据其各自溶解特性分类溶解,然后混合,加入双蒸水使各组分终浓度如上所述,得到溶液;
2)用5N HCl调节溶液的pH值至7.0,加氯化钠调节渗透压为285-305mOsm/kg,滤膜(0.22μm)过滤除菌滤后分装,保存至4℃。
本实施例中无血清无蛋白培养基在培养HEK293细胞中的应用,包括将HEK293细胞在上述培养基中培养72h,观察细胞形态(200×)。
从图1可以看出,培养3天后,HEK293F细胞状态良好且呈分散、悬浮形式正常生长。
实施例2
本实施例中支持HEK293细胞悬浮培养的无血清无蛋白培养基,除含有实施例1中的氨基酸、微量元素、维生素、脂类物质、无机盐、添加剂和抗结团物质外,还含有自噬抑制剂3-甲基腺嘌呤。在添加自噬抑制剂前,先将500mM 3-甲基腺嘌呤储备液溶解在0.5M HCl中,待细胞浓度达到峰值后一天加入3-甲基腺嘌呤至终浓度为10mM,然后用7.5%w/vNaHCO3溶液将培养物的pH值调节至7.0。
本实施例中无血清无蛋白培养基的制备方法同实施例1。
实施例3
本实施例中支持HEK293细胞悬浮培养的无血清无蛋白培养基,组成如下:
氨基酸组分:L-组氨酸盐酸盐一水合物100mg/L,L-异亮氨酸160mg/L,L-亮氨酸185mg/L,L-赖氨酸265mg/L,L-蛋氨酸55mg/L,L-苯丙氨酸100mg/L,L-苏氨酸165mg/L,L-色氨酸45mg/L,L-缬氨酸165mg/L,甘氨酸50mg/L,L-丙氨酸18mg/L,L-谷氨酰胺1600mg/L,L-精氨酸盐酸盐450mg/L,L-天(门)冬酰胺190mg/L,L-天冬氨酸45mg/L,L-半胱氨酸盐酸盐一水合物45mg/L,L-胱氨酸盐酸盐70mg/L,L-谷氨酸18mg/L,L-脯氨酸120mg/L,L-丝氨酸65mg/L,L-酪氨酸二钠盐二水合物175mg/L;
微量元素组分:偏钒酸铵0.0012mg/L,亚硒酸钠0.05mg/L,四水氯化亚锰0.3mg/L,五水硫酸铜0.3mg/L,氯化锌0.75mg/L;
维生素组分:维生素H(生物素)0.15mg/L,叶酸8mg/L,维生素B2(核黄素)0.5mg/L,硫辛酸0.3mg/L,维生素B12 2.5mg/L,i-肌醇30mg/L,维生素B6(盐酸吡哆醇)7mg/L,维生素B1(盐酸硫胺)5.5mg/L,维生素C 6mg/L,维生素E 2mg/L,D-泛酸钙5mg/L,烟酰胺4mg/L,氯化胆碱35mg/L;
脂类物质:亚麻酸0.15mg/L,地塞米松0.05mg/L,亚油酸0.12mg/L,胆固醇2mg/L,花生四烯酸0.005mg/L;
无机盐组分:柠檬酸铁80mg/L,柠檬酸钠140mg/L,磷酸氢二钠290mg/L,氯化钾305mg/L,碳酸氢钠2250mg/L,丙酮酸钠1050mg/L,硫酸镁95mg/L,硝酸钙230mg/L,柠檬酸苹果酸钙55mg/L;
添加剂:腐胺0.4mg/L,胸腺嘧啶1.0mg/L,抗坏血酸磷酸酯镁3mg/L,乙醇胺4mg/L,金精三羧酸3mg/L,次黄嘌呤6.0mg/L,甲基-β-环糊精55mg/L,甜菜碱650mg/L,牛磺酸150mg/L,海藻糖90mg/L,果糖1050mg/L,D-葡萄糖5500mg/L,酵母水解物2200mg/L,棉籽水解物1800mg/L,Kolliphor p188 5500mg/L;
抗结团物质:葡聚糖硫酸钠100mg/L,柠檬酸铁铵8mg/L;
余量为去离子水。
本实施例中无血清无蛋白培养基的制备方法同实施例1。待细胞浓度达到峰值后一天加入3-甲基腺嘌呤至终浓度为8mM,然后用7.5%w/v NaHCO3溶液将培养物的pH值调节至7.0。
实施例4
本实施例中支持HEK293细胞悬浮培养的无血清无蛋白培养基,组成如下:
氨基酸组分:L-组氨酸盐酸盐一水合物90mg/L,L-异亮氨酸170mg/L,L-亮氨酸170mg/L,L-赖氨酸280mg/L,L-蛋氨酸45mg/L,L-苯丙氨酸110mg/L,L-苏氨酸155mg/L,L-色氨酸55mg/L,L-缬氨酸150mg/L,甘氨酸60mg/L,L-丙氨酸10mg/L,L-谷氨酰胺1650mg/L,L-精氨酸盐酸盐435mg/L,L-天(门)冬酰胺210mg/L,L-天冬氨酸35mg/L,L-半胱氨酸盐酸盐一水合物60mg/L,L-胱氨酸盐酸盐55mg/L,L-谷氨酸25mg/L,L-脯氨酸110mg/L,L-丝氨酸80mg/L,L-酪氨酸二钠盐二水合物160mg/L;
微量元素组分:偏钒酸铵0.0008mg/L,亚硒酸钠0.07mg/L,四水氯化亚锰0.1mg/L,五水硫酸铜0.5mg/L,氯化锌0.5mg/L;
维生素组分:维生素H(生物素)0.05mg/L,叶酸12mg/L,维生素B2(核黄素)0.3mg/L,硫辛酸0.5mg/L,维生素B12 1.5mg/L,i-肌醇40mg/L,维生素B6(盐酸吡哆醇)5mg/L,维生素B1(盐酸硫胺)7.5mg/L,维生素C 4mg/L,维生素E 3mg/L,D-泛酸钙4mg/L,烟酰胺6mg/L,氯化胆碱25mg/L;
脂类物质:亚麻酸0.05mg/L,地塞米松0.15mg/L,亚油酸0.2mg/L,胆固醇3mg/L,花生四烯酸0.001mg/L;
无机盐组分:柠檬酸铁70mg/L,柠檬酸钠155mg/L,磷酸氢二钠280mg/L,氯化钾315mg/L,碳酸氢钠2150mg/L,丙酮酸钠1150mg/L,硫酸镁85mg/L,硝酸钙240mg/L,柠檬酸苹果酸钙45mg/L;
添加剂:腐胺0.3mg/L,胸腺嘧啶1.5mg/L,抗坏血酸磷酸酯镁2mg/L,乙醇胺6mg/L,金精三羧酸2mg/L,次黄嘌呤7.5mg/L,甲基-β-环糊精45mg/L,甜菜碱750mg/L,牛磺酸100mg/L,海藻糖110mg/L,果糖950mg/L,D-葡萄糖6500mg/L,酵母水解物1800mg/L,棉籽水解物2200mg/L,Kolliphor p188 45000mg/L;
抗结团物质:葡聚糖硫酸钠150mg/L,柠檬酸铁铵8~12mg/L;
余量为去离子水。
本实施例中无血清无蛋白培养基的制备方法同实施例1。
实施例5
本实施例中支持HEK293细胞悬浮培养的无血清无蛋白培养基,组成如下:
氨基酸组分:L-组氨酸盐酸盐一水合物50mg/L,L-异亮氨酸200mg/L,L-亮氨酸150mg/L,L-赖氨酸300mg/L,L-蛋氨酸25mg/L,L-苯丙氨酸150mg/L,L-苏氨酸100mg/L,L-色氨酸75mg/L,L-缬氨酸100mg/L,甘氨酸75mg/L,L-丙氨酸6mg/L,L-谷氨酰胺2000mg/L,L-精氨酸盐酸盐200mg/L,L-天(门)冬酰胺300mg/L,L-天冬氨酸20mg/L,L-半胱氨酸盐酸盐一水合物75mg/L,L-胱氨酸盐酸盐40mg/L,L-谷氨酸30mg/L,L-脯氨酸55mg/L,L-丝氨酸150mg/L,L-酪氨酸二钠盐二水合物100mg/L;
微量元素组分:偏钒酸铵0.0001mg/L,亚硒酸钠0.25mg/L,四水氯化亚锰0.1mg/L,五水硫酸铜0.6mg/L,氯化锌0.2mg/L;
维生素组分:维生素H(生物素)0.01mg/L,叶酸20mg/L,维生素B2(核黄素)0.1mg/L,硫辛酸1mg/L,维生素B12 0.5mg/L,i-肌醇60mg/L,维生素B6(盐酸吡哆醇)2mg/L,维生素B1(盐酸硫胺)10mg/L,维生素C 2.5mg/L,维生素E10mg/L,D-泛酸钙1mg/L,烟酰胺10mg/L,氯化胆碱20mg/L;
脂类物质:亚麻酸0.008mg/L,地塞米松0.8mg/L,亚油酸0.05mg/L,胆固醇10mg/L,花生四烯酸0.0002mg/L;
无机盐组分:柠檬酸铁50mg/L,柠檬酸钠200mg/L,磷酸氢二钠150mg/L,氯化钾500mg/L,碳酸氢钠2000mg/L,丙酮酸钠1500mg/L,硫酸镁50mg/L,硝酸钙300mg/L,柠檬酸苹果酸钙25mg/L;
添加剂:腐胺0.1mg/L,胸腺嘧啶2.4mg/L,抗坏血酸磷酸酯镁1mg/L,乙醇胺12.5mg/L,金精三羧酸1mg/L,次黄嘌呤10mg/L,甲基-β-环糊精25mg/L,甜菜碱1000mg/L,牛磺酸60mg/L,海藻糖150mg/L,果糖500mg/L,D-葡萄糖8000mg/L,酵母水解物1000mg/L,棉籽水解物3000mg/L,Kolliphor p188 3000mg/L;
抗结团物质:葡聚糖硫酸钠100mg/L,柠檬酸铁铵15mg/L;
余量为去离子水。
本实施例中无血清无蛋白培养基的制备方法同实施例1。
实施例6
本实施例中支持HEK293细胞悬浮培养的无血清无蛋白培养基,组成如下:
氨基酸组分:L-组氨酸盐酸盐一水合物150mg/L,L-异亮氨酸100mg/L,L-亮氨酸200mg/L,L-赖氨酸250mg/L,L-蛋氨酸100mg/L,L-苯丙氨酸50mg/L,L-苏氨酸200mg/L,L-色氨酸25mg/L,L-缬氨酸200mg/L,甘氨酸25mg/L,L-丙氨酸25mg/L,L-谷氨酰胺1000mg/L,L-精氨酸盐酸盐600mg/L,L-天(门)冬酰胺150mg/L,L-天冬氨酸60mg/L,L-半胱氨酸盐酸盐一水合物25mg/L,L-胱氨酸盐酸盐100mg/L,L-谷氨酸10mg/L,L-脯氨酸165mg/L,L-丝氨酸50mg/L,L-酪氨酸二钠盐二水合物200mg/L;
微量元素组分:偏钒酸铵0.1mg/L,亚硒酸钠0.01mg/L,四水氯化亚锰0.5mg/L,五水硫酸铜0.1mg/L,氯化锌1.0mg/L;
维生素组分:维生素H(生物素)1mg/L,叶酸5mg/L,维生素B2(核黄素)1mg/L,硫辛酸0.1mg/L,维生素B12 4mg/L,i-肌醇20mg/L,维生素B6(盐酸吡哆醇)10mg/L,维生素B1(盐酸硫胺)2mg/L,维生素C10mg/L,维生素E1mg/L,D-泛酸钙10mg/L,烟酰胺1mg/L,氯化胆碱60mg/L;
脂类物质:亚麻酸0.8mg/L,地塞米松0.008mg/L,亚油酸0.5mg/L,胆固醇1mg/L,花生四烯酸0.02mg/L;
无机盐组分:柠檬酸铁150mg/L,柠檬酸钠100mg/L,磷酸氢二钠300mg/L,氯化钾300mg/L,碳酸氢钠3000mg/L,丙酮酸钠750mg/L,硫酸镁150mg/L,硝酸钙100mg/L,柠檬酸苹果酸钙100mg/L;
添加剂:腐胺1mg/L,胸腺嘧啶0.6mg/L,抗坏血酸磷酸酯镁5mg/L,乙醇胺1.5mg/L,金精三羧酸10mg/L,次黄嘌呤1mg/L,甲基-β-环糊精100mg/L,甜菜碱500mg/L,牛磺酸180mg/L,海藻糖75mg/L,果糖1500mg/L,D-葡萄糖4000mg/L,酵母水解物3000mg/L,棉籽水解物1000mg/L,Kolliphor p188 6000mg/L;
抗结团物质:葡聚糖硫酸钠50mg/L,柠檬酸铁铵5mg/L;
余量为双蒸水。
本实施例中无血清无蛋白培养基的制备方法同实施例1。
试验例1
采用实施例2中无血清无蛋白培养基,将已经驯化好的HEK293F细胞在30mL的培养皿中连续培养5天,细胞观察生长以及进行总细胞计数和活细胞计数。
从图2可以看出,HEK293F细胞起始接种密度为8.5×105cells/mL,在转速为95rpm条件下,37℃、5%CO2培养5天后,细胞最高密度达到4.7×106cells/mL,活率维持在92%。
试验例2
在温度37℃条件下培养,在三个六孔板中分别接种2×106HEK293细胞,待细胞密度约80%进行转染。具体操作步骤如下:将30μL lipofectamine 2000加入到720μL Opti-MEM培养基,在37℃孵箱中静置5min,将上述脂质体与Opti-MEM培养基的混合物与750μL(15μg)含TGF-β1基因的表达载体混合,37℃孵箱中静置20min;同时用PBS将六孔培养板内的细胞清洗三遍后,加入2mL无血清的DMEM细胞培养基;然后将脂质体与转染质粒的混合液100μL逐滴加入每孔中(每六孔板五个复孔,一个对照孔),并尽快轻轻摇晃培养平板使其混匀。待细胞培养48小时后,800μg/mL G418筛选7天后胰酶消化离心后收集细胞。收集三个六孔板内的细胞分别采用国外品牌(Gibco)、实施例1和实施例2中无血清无蛋白培养基,置于125mL摇瓶中,400μg/mL G418筛选。在37℃孵箱中,5%CO2,转速为95rpm条件下培养5d,收集上清蛋白进行浓缩后进行Western blot试验,验证外源基因TGF-β1在不同培养基中的表达情况。试验结果如图3所示,图中A:Western blot试验验证不同培养基中TGF-B1的表达情况;B:Western blot试验的统计结果。
从图3可以看出,实施例1中无血清无蛋白培养基表达蛋白水平与国外品牌(Gibco)没有差异,实施例2中加入3-甲基腺嘌呤后,TGF-β1表达量明显提高。
需要说明的是:上述虽然结合实施例对本发明的具体实施方式进行了描述,但并非对本发明保护范围的限制,所属领域技术人员应该明白,在本发明的技术方案的基础上,凡是采用等同替换或等效变换形成的任何技术方案,均落在本发明要求的保护范围内。
Claims (10)
1.一种支持HEK293细胞悬浮培养的无血清无蛋白培养基,包括氨基酸、微量元素、维生素、脂类物质、无机盐,其特征在于:所述无血清无蛋白培养基中还包括抗结团物质和添加剂;所述抗结团物质的组成为:葡聚糖硫酸钠25~150mg/L,柠檬酸铁铵5~15mg/L;所述添加剂的组成为:腐胺0.1~1mg/L,胸腺嘧啶0.6~2.4mg/L,抗坏血酸磷酸酯镁1~5mg/L,乙醇胺1.5~12.5mg/L,金精三羧酸1~10mg/L,次黄嘌呤1~10mg/L,甲基-β-环糊精25~100mg/L,甜菜碱500~1000mg/L,牛磺酸60~180mg/L,海藻糖75~150mg/L,果糖500~1500mg/L,D-葡萄糖4000~8000mg/L,酵母水解物1000~3000mg/L,棉籽水解物1000~3000mg/L,Kolliphor p1883000~6000mg/L;
所述支持HEK293细胞悬浮培养的无血清无蛋白培养基中还包括3-甲基腺嘌呤,在细胞浓度达到峰值后一天加入3-甲基腺嘌呤至终浓度为8~12mmol/L;
所述支持HEK293细胞悬浮培养的无血清无蛋白培养基用于TGF-β1基因的表达。
2.根据权利要求1所述的无血清无蛋白培养基,其特征在于:所述抗结团物质的组成为:葡聚糖硫酸钠50~120mg/L,柠檬酸铁铵8~12mg/L。
3.根据权利要求1所述的无血清无蛋白培养基,其特征在于:所述添加剂的组成为:腐胺0.3~0.4mg/L,胸腺嘧啶1.0~1.5mg/L,抗坏血酸磷酸酯镁2~3mg/L,乙醇胺4~6mg/L,金精三羧酸2~3mg/L,次黄嘌呤6.0~7.5mg/L,甲基-β-环糊精45~55mg/L,甜菜碱650~750mg/L,牛磺酸100~150mg/L,海藻糖90~110mg/L,果糖950~1050mg/L,D-葡萄糖5500~6500mg/L,酵母水解物1800~2200mg/L,棉籽水解物1800~2200mg/L,Kolliphor p188 4500~5500mg/L。
4.根据权利要求1所述的无血清无蛋白培养基,其特征在于:所述氨基酸的组成为:L-组氨酸盐酸盐一水合物50~150mg/L,L-异亮氨酸100~200mg/L,L-亮氨酸150~200mg/L,L-赖氨酸250~300mg/L,L-蛋氨酸25~100mg/L,L-苯丙氨酸50~150mg/L,L-苏氨酸100~200mg/L,L-色氨酸25~75mg/L,L-缬氨酸100~200mg/L,甘氨酸25~75mg/L,L-丙氨酸6~25mg/L,L-谷氨酰胺1000~2000mg/L,L-精氨酸盐酸盐200~600mg/L,L-天(门)冬酰胺150~300mg/L,L-天冬氨酸20~60mg/L,L-半胱氨酸盐酸盐一水合物25~75mg/L,L-胱氨酸盐酸盐40~100mg/L,L-谷氨酸10~30mg/L,L-脯氨酸55~165mg/L,L-丝氨酸50~150mg/L,L-酪氨酸二钠盐二水合物100~200mg/L。
5.根据权利要求1所述的无血清无蛋白培养基,其特征在于:所述微量元素的组成为:偏钒酸铵0.0001~0.1mg/L,亚硒酸钠0.01~0.25mg/L,四水氯化亚锰0.1~0.5mg/L,五水硫酸铜0.1~0.6mg/L,氯化锌0.2~1.0mg/L。
6.根据权利要求1所述的无血清无蛋白培养基,其特征在于:所述维生素的组成为:维生素H 0.01~1mg/L,叶酸5~20mg/L,维生素B2 0.1~1mg/L,硫辛酸0.1~1mg/L,维生素B120.5~4mg/L,i-肌醇20~60mg/L,维生素B6 2~10mg/L,维生素B1 2~10mg/L,维生素C 2.5~10mg/L,维生素E 1~10mg/L,D-泛酸钙 1~10mg/L,烟酰胺1~10mg/L,氯化胆碱20~60mg/L。
7.根据权利要求1所述的无血清无蛋白培养基,其特征在于:所述脂类物质的组成为:亚麻酸0.008~0.8mg/L,地塞米松0.008~0.8mg/L,亚油酸0.05~0.5mg/L,胆固醇1~10mg/L,花生四烯酸0.0002~0.02mg/L。
8.根据权利要求1所述的无血清无蛋白培养基,其特征在于:所述无机盐的组成为:柠檬酸铁50~150mg/L,柠檬酸钠100~200mg/L,磷酸氢二钠150~300mg/L,氯化钾300~500mg/L,碳酸氢钠2000~3000mg/L,丙酮酸钠750~1500mg/L,硫酸镁50~150mg/L,硝酸钙100~300mg/L,柠檬酸苹果酸钙25~100mg/L。
9.如权利要求1所述的支持HEK293细胞悬浮培养的无血清无蛋白培养基的制备方法,其特征在于:包括以下步骤:
1)按照配方准确称取培养基中各组分,在水中溶解混合,得到溶液;
2)调节溶液的pH值为6.9~7.2、渗透压为285-305mOsm/kg,过滤除菌,即得。
10.如权利要求1所述的支持HEK293细胞悬浮培养的无血清无蛋白培养基在培养HEK293细胞中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010108434.9A CN111304149B (zh) | 2020-02-21 | 2020-02-21 | 一种支持hek293细胞悬浮培养的无血清无蛋白培养基及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010108434.9A CN111304149B (zh) | 2020-02-21 | 2020-02-21 | 一种支持hek293细胞悬浮培养的无血清无蛋白培养基及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111304149A CN111304149A (zh) | 2020-06-19 |
CN111304149B true CN111304149B (zh) | 2022-07-05 |
Family
ID=71149058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010108434.9A Active CN111304149B (zh) | 2020-02-21 | 2020-02-21 | 一种支持hek293细胞悬浮培养的无血清无蛋白培养基及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111304149B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111793595A (zh) * | 2020-07-23 | 2020-10-20 | 上海奥浦迈生物科技有限公司 | 一种hek293细胞无血清培养基 |
CN111826341A (zh) * | 2020-07-23 | 2020-10-27 | 上海奥浦迈生物科技有限公司 | 一种体外培养hek293细胞用于瞬时表达蛋白的方法 |
CN114075540B (zh) * | 2020-08-21 | 2023-10-13 | 苏州新微溪生物医药有限公司 | 全化学成分hek293细胞培养基及其应用 |
CN113061584A (zh) * | 2021-05-14 | 2021-07-02 | 赵峻岭 | 一种能促进腺病毒生长的培养基添加物 |
CN114438131A (zh) * | 2022-02-25 | 2022-05-06 | 上海健士拜生物科技有限公司 | 293细胞的转染方法 |
CN114736871A (zh) * | 2022-04-27 | 2022-07-12 | 中山康晟生物技术有限公司 | 一种腺病毒包装wayne293 lvpro动物细胞培养方法 |
CN114854695B (zh) * | 2022-05-24 | 2022-12-27 | 广州蕊特生物科技有限公司 | 提高β-2微球蛋白在HEK-293细胞中表达水平的细胞转染培养方法 |
CN115369069B (zh) * | 2022-08-22 | 2023-12-19 | 上海健士拜生物科技有限公司 | 293细胞补料培养基及其制备和应用 |
CN116515737B (zh) * | 2023-06-28 | 2023-09-22 | 苏州依科赛生物科技股份有限公司 | 一种hek293细胞和cho细胞通用培养基及应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
CN1772884A (zh) * | 2005-10-18 | 2006-05-17 | 中国人民解放军军事医学科学院生物工程研究所 | 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基 |
CN101220347A (zh) * | 2007-12-28 | 2008-07-16 | 天津百若克医药生物技术有限责任公司 | 一种人胚肾293细胞扩增无蛋白培养基 |
CN106399224A (zh) * | 2016-12-13 | 2017-02-15 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
CN106635953A (zh) * | 2016-12-13 | 2017-05-10 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
CN109294976A (zh) * | 2018-11-13 | 2019-02-01 | 王晓柯 | 一种支持hek293细胞悬浮培养的无血清培养基 |
-
2020
- 2020-02-21 CN CN202010108434.9A patent/CN111304149B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
CN1772884A (zh) * | 2005-10-18 | 2006-05-17 | 中国人民解放军军事医学科学院生物工程研究所 | 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基 |
CN101220347A (zh) * | 2007-12-28 | 2008-07-16 | 天津百若克医药生物技术有限责任公司 | 一种人胚肾293细胞扩增无蛋白培养基 |
CN106399224A (zh) * | 2016-12-13 | 2017-02-15 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
CN106635953A (zh) * | 2016-12-13 | 2017-05-10 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
CN109294976A (zh) * | 2018-11-13 | 2019-02-01 | 王晓柯 | 一种支持hek293细胞悬浮培养的无血清培养基 |
Non-Patent Citations (1)
Title |
---|
适应无血清培养的 HEK293 细胞系的培育;孟其麟等;《中国预防兽医学报》;20120530;第34卷(第5期);第375-378页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111304149A (zh) | 2020-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111304149B (zh) | 一种支持hek293细胞悬浮培养的无血清无蛋白培养基及其制备方法和应用 | |
AU2011246503B2 (en) | Improved cell culture medium | |
US6048728A (en) | Cell culture medium for enhanced cell growth, culture longevity, and product expression | |
RU2011116319A (ru) | Производство высокого титра антител | |
EP2563903B1 (en) | Improved cell culture medium | |
DK2167644T3 (en) | CULTURAL MEDIA FOR DEVELOPING CELLS CONTAINING INCREASED LIPONIC ACID CONCENTRATIONS | |
CN107460159A (zh) | 无血清、无蛋白补料培养基及其制备方法和运用 | |
CN102317440B (zh) | 改进的培养基添加剂及其应用方法 | |
CN104450607B (zh) | 用于hek293细胞悬浮生长的全化学成分培养基及培养方法 | |
CN101418330A (zh) | 适于nso细胞大规模培养及抗体生产的无蛋白培养基 | |
CN101195817A (zh) | 一种杂交瘤细胞扩增培养基及其用途 | |
CN111996161A (zh) | 一种cho细胞无血清无蛋白培养基及其用途 | |
KR102601321B1 (ko) | 세포 내 글루타티온 수준을 증가시키는 방법 | |
CN103421736B (zh) | Cho细胞培养中替代动物血清的培养基添加剂及其配制方法 | |
JPS5974982A (ja) | 細胞をインビトロで生長させるための細胞生長培地補足剤およびそのための方法 | |
CN114854695B (zh) | 提高β-2微球蛋白在HEK-293细胞中表达水平的细胞转染培养方法 | |
EP0817837A1 (en) | Culture medium for insect cells | |
Hu | Medium design for cell culture processing | |
CN109536435A (zh) | 一种无血清无蛋白培养基 | |
JPH0568231B2 (zh) | ||
Deer et al. | DEVELOPMENT OF A FED-BATCH STRATEGY THAT UTILIZES MULTIPLE CARBON SOURCES TO MAXIMIZE RECOMBINANT PROTEIN EXPRESSION IN CHO CELLS | |
CN117778299A (zh) | 一种用于cho细胞高效表达重组胶原蛋白的无血清培养基 | |
JPH03266981A (ja) | 動物細胞用合成培地 | |
RU2798069C2 (ru) | Улучшенная среда для культивирования клеток | |
KAPLANL | The Regulation of Intermediary Amino |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |